Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Marseille, Elliot ^a   Giganti, Mark J ^b   Mwango, Albert ^c   Chisembele Taylor, Angela ^b   Mulenga, Lloyd ^b   Over, Mead ^d   Kahn, James G ^e,f   Stringer, Jeffrey S A ^b  

^a Health Strategies International   (United States)

^b CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^c MINISTRY OF HEALTH   (Zambia)

^d CENTER FOR GLOBAL DEVELOPMENT   (United States)

^e Super Models for Global Health   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADL DISABILITY; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE FINANCING; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; QUALITY ADJUSTED LIFE YEAR; RURAL POPULATION; ZAMBIA;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; HIV INFECTIONS; HUMANS; ZAMBIA;

EID: 84871434669     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051993     Document Type: Article

References (37)

1. UNAIDS/WHO (2008) Epidemiological Fact Sheet on HIV and AIDS: Core data on epidemiology and response: 2008 Update. Available: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_HT.pdf. Accessed 2012 Nov 24.
2. AVERTing HIV and AIDS (2011) President's Emergency Plan for AIDS Relief (PEPFAR). United Kingdom: AVERT. Available: http://www.avert.org/pepfar.htm. Accessed 2012 Nov 24.
3. Government of the Republic of Zambia (2010) Zambia Country Report: Monitoring the Declaration of Commitment on HIV and AIDS and the Universal Access Biennial Report.
4. UNAIDS (2008) 2008 report on the global HIV/AIDS epidemic. Geneva: UNAIDS. 236 p.
5. World Health Organization (2007) Maternal mortality in 2005: estimates developed by WHO, UNICEF, UNFPA, and the World Bank. Geneva: UNAIDS. 48 p.
6. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) (2011) PEPFAR Operational Plan. Washinghton, DC: Office of U.S. Global AIDS Coordinator. 147 p.
7. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, et al. (2007) Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. JAMA 298: 1888-1899.
8. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, et al. (2006) Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 296: 782-793.
9. World Bank (1993) World Development Report 1993: Investing in Health. New York: Oxford University Press.
10. Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, et al. (2006) Disease Control Priorities in Developing Countries, second edition. New York: Oxford University Press. 1394 p.
11. Sikka R, Xia F, Aubert RE, (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11: 449-457.
12. Dezii CM, (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10: 42-45.
13. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997) Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications. 305 p.
14. Mermin J, Were W, Ekwaru JP, Moore D, Downing R, et al. (2008) Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet 371: 752-759.
15. Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, et al. (2009) The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 7: 229-243.
16. Morgan MG, Henrion M (1990) Uncertainty: A Guide to Deaing with Uncertainty in Quantitative Risk and Policy Analysis. Cambridge: Cambridge University Press. 332 p.
17. Mermin J, Lule J, Ekwaru JP, Downing R, Hughes P, et al. (2005) Cotrimoxazole prophylaxis by HIV-infected persons in Uganda reduces morbidity and mortality among HIV-uninfected family members. Aids 19: 1035-1042.
18. Kombe G, Galaty D, Gadhia R, Decker C (2005) The Human and Financial Resource Requirements for Scaling Up HIV/AIDS Services in Ethiopia. Report by PHRplus and Abt Associates to USAID. Available: http://www.abtassociates.com/reports/AB_PNADC109.pdf. Accessed 2012 Nov 24.
19. Kombe G, Smith O, Nwagbara C (2004) Scaling Up Antiretroviral Treatment in the Public Sector in Nigeria: A Comprehensive Analysis of Resource Requirements. Report issued by PHRplus and Abt Associates. Available: http://www.phrplus.org/Pubs/Tech037_fin.pdf. Accessed 2012 Nov 24.
20. Kombe G, Smith O (2003) Application of the AIDSTREATCOST model to estimate the cost of ARV treatment in Zambia and Uganda. Power Point presentation produced by PHRplus, Abt Associates, and USAID.
21. Boulle A, Kenyon C, Skordis J, Wood R, (2002) Exploring the costs of a limited public sector antiretroviral treatment programme in South Africa. South African Medical Journal 92: 811-817.
22. Govender V, McIntyre D, Grimwood A, Maartens G (2000) The Costs and Perceived Quality of Care for People Living with HIV/AIDS in the Western Cape Province in South Africa. Report from PHR and Abt Associates to USAID. Available: http://phrplus.org/Pubs/sar14.pdf. Accessed 2012 Nov 24.
23. Geffen N, Nattrass N, Raubenheimer C (2003) The Cost of HIV Prevention and Treatment interventions in South Africa. Report issued by Center for Social Science Research, AIDS and Society Research Unit, University of Cape Town. Available: http://www.hst.org.za/publications/cost-hiv-prevention-and-treatment-interventions-south-africa-0. Accessed 2012 Nov 24.
24. Cleary S, Jikwana S, Boulle A (2004b) Resource Requirements for Comprehensive HIV and AIDS Care, Management and Treatment in South Africa: March 2004-March 2009 South African Health Review 2005. Durban: South African Health Systems Trust.
25. Bikilla AD, Jerene D, Robberstad B, Lindtjorn B, (2009) Cost estimates of HIV care and treatment with and without anti-retroviral therapy at Arba Minch Hospital in southern Ethiopia. Cost Eff Resour Alloc 7: 6.
26. Hounton SH, Akonde A, Zannou DM, Bashi J, Meda N, et al. (2008) Costing universal access of highly active antiretroviral therapy in Benin. AIDS Care 20: 582-587.
27. Kevany S, Meintjes G, Rebe K, Maartens G, Cleary S, (2009) Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital). S Afr Med J 99: 320-325.
28. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA, (2005) Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ 331: 1431.
29. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, et al. (2005) Cost-Effectiveness of Highly Active Antiretroviral Therapy in South Africa. PLoS Med 3: e4.
30. Cleary S, Boulle A, McIntyre D, Coetzee D (2004) Cost-effectiveness of antiretroviral treatment for HIV-positive adults in a South African township. Cape Town: Médecins Sans Frontières, Health Systems Trust, University of Capetown. 67 p.
31. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Cote d'Ivoire. N Engl J Med 355: 1141-1153.
32. Donald PR, van Helden PD, (2009) The global burden of tuberculosis-combating drug resistance in difficult times. N Engl J Med 360: 2393-2395.
33. Babigumira JB, Sethi AK, Smyth KA, Singer ME, (2009) Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics 27: 963-973.
34. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895-1905.
35. Zwillich T, (2009) Obama administration may flat-line funding for PEPFAR. Lancet 373: 1325.
36. Galarraga O, Wirtz VJ, Figueroa-Lara A, Santa-Ana-Tellez Y, Coulibaly I, et al. (2011) Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV: A Systematic Review for Low- and Middle-Income Countries. Pharmacoeconomics 29: 579-599.
37. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents-November 2009. Geneva: WHO. 25 p.